Deep Vein Thrombosis News and Research

RSS

Deep vein thrombosis, or DVT, is a blood clot that forms in a vein deep in the body. Most deep vein clots occur in the lower leg or thigh. If the vein swells, the condition is called thrombophlebitis. A deep vein thrombosis can break loose and cause a serious problem in the lung, called a pulmonary embolism, or a heart attack or stroke.

New technology removes blood clots

When a large blood clot was discovered attached to the end of a catheter inside the right atrial chamber of a patient's heart, doctors faced a daunting challenge.

10 Jul 2014

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Boehringer Ingelheim today announces that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

6 Jun 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

New approach can improve patient outcomes, reduce complications in complex spine surgeries

A new team approach has improved safety-reducing rates of major complications by two thirds-for complex spinal reconstructive surgery for spinal deformity in adult Group Health patients at Virginia Mason Hospital & Seattle Medical Center.

27 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

Study finds higher readmission rates for same-day total joint replacement surgery

As the effectiveness of anesthesia, pain management and rehabilitation continues to improve, more orthopaedic procedures are being done on an outpatient basis. In a new research study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons, same-day total joint replacement (TJR) patient outcomes were comparable to those of patients admitted to the hospital and staying at least one night following surgery.

14 Mar 2014

Statins combined with conventional blood clot prevention therapies, reduce VTE risk by 48%

Statins have long been known to lower cholesterol and, more recently, to decrease the risk of deep vein thrombosis (blood clots) in healthy, non-surgical patients.

11 Mar 2014

Long-term risks of deep vein thrombosis

Deep vein thrombosis (DVT) often brings with it the risk of post-thrombotic syndrome (PTS), an under-recognized but serious complication that often causes long-term disability for patients. During March's DVT Awareness Month, the Society of Interventional Radiology wants to help patients and family members to better understand the long-term risks of DVT.

5 Mar 2014

Mobile compression device just as effective as blood thinners in preventing DVT after joint surgery

Research from The Shiley Center for Orthopaedic Research and Education at Scripps Clinic could change how patients are treated to prevent blood clots after joint replacement surgery. A study published as the lead article in the current issue of the Journal of Bone and Joint Surgery determined that after lower extremity joint replacement surgery a mobile compression device was just as effective as blood thinners in preventing deep vein thrombosis (DVT), but without negative side effects including bleeding complications.

15 Feb 2014

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby, says study

Women's blood clot risk remains elevated for at least 12 weeks after delivering a baby - twice as long as previously recognized, according to a large study presented at the American Stroke Association's International Stroke Conference 2014.

14 Feb 2014

Research helps identify stroke patients at risk for mortality and treatments to reduce death rate

For patients who have experienced a large stroke that cuts off blood supply to a large part of the brain, the use of standardized medical management protocol and surgery to decompress swelling can improve life expectancy, Mayo Clinic researchers found in a recent study.

28 Jan 2014

Use of standardized medical management protocol and surgery can improve life expectancy

28 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Daiichi Sankyo submits Marketing Authorization Application for edoxaban to EMA

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency.

7 Jan 2014

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.

11 Dec 2013

WHO releases new report on spinal cord injury

As many as 500 000 people suffer a spinal cord injury each year. People with spinal cord injuries are 2 to 5 times more likely to die prematurely, with worse survival rates in low- and middle-income countries. The new WHO report, "International perspectives on spinal cord injuries", summarizes the best available evidence on the causes, prevention, care and lived experience of people with spinal cord injury.

2 Dec 2013

Researchers explore strategies that would optimize fresher blood for patients

Although clinical evidence is lacking on the relationship between the storage time of red blood cells and outcomes in transfused patients, the authors of a review article in the November 2013 issue of The Annals of Thoracic Surgery are advocating for a modernized blood management system—similar to inventory management systems seen in the retail sector—to potentially reduce patient complications.

31 Oct 2013

MRSA musculoskeletal infections increasing among children

Pediatric musculoskeletal Staphylococcus aureus bacterial infections have been evolving over the past decade, with more children diagnosed with the more virulent, methicillin-resistant Staphylococcus aureus today than 10 years ago.

28 Oct 2013

Detecting dangerous blood clots in the form of simple urine test

Detecting dangerous blood clots, which can cause life-threatening conditions such as strokes and heart attacks, leading causes of death for men and women in the U.S., has been a coveted and elusive goal.

17 Oct 2013